PolyPid
$ 4.57
2.24%
06 Jan - close price
- Market Cap 76,021,000 USD
- Current Price $ 4.57
- High / Low $ 4.64 / 4.47
- Stock P/E N/A
- Book Value 0.92
- EPS -2.81
- Next Earning Report 2026-02-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.88 %
- ROE -3.90 %
- 52 Week High 4.64
- 52 Week Low 2.30
About
PolyPid Ltd. is a pioneering biopharmaceutical company based in Petah Tikva, Israel, focused on advancing innovative therapies through its proprietary Polymer Lipid Encapsulation Matrix (PLEX) technology. The company is dedicated to targeting local infections and enhancing surgical outcomes, addressing significant unmet medical needs in the healthcare sector. With a robust pipeline and a commitment to research and development, PolyPid is well-positioned to form strategic collaborations and capitalize on its cutting-edge technology to meet the dynamic demands of the market, potentially transforming patient care and driving substantial growth.
Analyst Target Price
$12.25
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-13 | 2025-05-14 | 2025-02-12 | 2024-11-13 | 2024-08-14 | 2024-05-08 | 2024-02-14 | 2023-11-08 | 2023-08-09 | 2023-05-10 | 2023-02-08 |
| Reported EPS | -0.37 | -0.78 | -0.7 | -1.07 | -1.22 | -1.25 | -1.37 | -3.84 | -3.4 | -10.8 | -8.4 | -9.6 |
| Estimated EPS | -0.52 | -0.55 | -0.82 | -0.88 | -1 | -1.3 | -1.41 | -4.29 | -4.43 | -13.32 | -4.8 | -12.36 |
| Surprise | 0.15 | -0.23 | 0.12 | -0.19 | -0.22 | 0.05 | 0.04 | 0.45 | 1.03 | 2.52 | -3.6 | 2.76 |
| Surprise Percentage | 28.8462% | -41.8182% | 14.6341% | -21.5909% | -22% | 3.8462% | 2.8369% | 10.4895% | 23.2506% | 18.9189% | -75% | 22.3301% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-11 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.34 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PYPD
2026-01-01 02:09:42
PolyPid Ltd. (PYPD) has scheduled an Extraordinary General Meeting of Shareholders for February 4, 2026, to approve the compensation terms for its board chair, Ms. Brooke Story. Shareholders of record on January 5, 2026, are eligible to vote. The proposal is part of the company's continuous efforts toward formalizing its corporate governance framework.
2025-12-28 17:09:58
PolyPid Ltd. (NASDAQ:PYPD) experienced a significant increase in short interest during December, rising 72.2% to 63,411 shares. Despite this, the short-interest ratio remains low at 0.6 days. Institutional investors, including AIGH Capital Management LLC, hold a substantial portion of the company's stock, and analysts maintain a "Moderate Buy" rating with a consensus price target of $12.40.
2025-12-19 05:08:58
PolyPid Ltd. (Nasdaq: PYPD), a biopharma company, announced the appointment of Brooke Story as Chairman of the Board of Directors, effective December 11, 2025. Ms. Story brings over 25 years of MedTech industry experience, including senior roles at BD and Medtronic PLC, focusing on surgical markets and corporate strategy. This appointment aims to bolster PolyPid's strategic, commercial, and transactional capabilities ahead of its D-PLEX₁₀₀ New Drug Application submission.
2025-12-18 03:09:42
PolyPid Ltd. announced the appointment of Brooke Story as Chairman of the Board of Directors, effective December 11, 2025, bringing over 25 years of MedTech leadership experience to the role. This appointment is significant as PolyPid prepares for the New Drug Application submission of D-PLEX100, aiming to commercialize its clinical success. Despite promising clinical advancements, TipRanks' AI Analyst "Spark" rates PYPD as Neutral due to significant financial challenges and an unattractive valuation.
2025-12-17 07:11:13
PolyPid Ltd. announced the appointment of Brooke Story as Chairman of the Board of Directors, effective December 11, 2025. Story brings over 25 years of MedTech leadership experience from companies like BD and Medtronic PLC, with expertise in surgical markets, infection prevention, and corporate development. Her appointment is expected to enhance PolyPid’s strategic, commercial, and transactional capabilities as it prepares for the D-PLEX₁₀₀ New Drug Application submission.
2025-12-16 14:46:07
PolyPid Ltd. has appointed Brooke Story as Chairman of the Board of Directors, effective December 11, 2025. This move aims to leverage Story's extensive MedTech experience in surgical markets and corporate strategy to transition PolyPid from clinical success to commercial application, particularly for its lead product D-PLEX100. The company anticipates submitting a New Drug Application for D-PLEX100 in early 2026 to address surgical site infections.
